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ABSTRACT
INTRODUCTION In the last decade, outpatient smoking cessation clinics (SCCs) in 
Turkey have been extended countrywide. Initially, only counseling was covered 
under health insurance. In 2011 and 2015, free varenicline and bupropion 
preparations were distributed to SCCs, periodically. In the current study we 
aimed to compare outcomes between the free and paid medication periods. 
METHODS  Patients applied to the local SCC in a secondary health care unit between 
June 2014 and June 2017. They were evaluated for SC interventions and had 
phone visits after their third month; these records were included in the study. 
Patients were grouped and evaluated according to medication’s reimbursement 
status: free medication period (FP) and paid medication period (PMP). 
RESULTS  In total, 733 patients applied to the SCC, 77.7% of them had applied 
during the FP. Analyses were made involving 417 patients who had records of 
third-month phone visit. Mean age of the patients was 44.0±13.7 years with 
the majority of patients (65%) being male. Sociodemographic characteristics of 
patients in both groups were not statistically different, while the percentage of 
patients with comorbid diseases was lower in the FP group (p<0.05). Treatment 
choices were different— the bupropion-prescribed group’s rate was similar in 
both periods (53.5% in PMP vs 52.0% in FP), however varenicline was mostly 
prescribed in the FP (35.8% vs 14.1%) while nicotine replacement therapy was 
mostly prescribed in the PMP (32.4% vs 12.1%) (p<0.05). Patients who used 
the advised treatment for at least 30 days (treatment adherent) and the rate of 
quitters at the third month were higher in FP (p<0.05) from univariate analysis, 
however these differences were not statistically significant when a multivariate 
analysis was performed. 
CONCLUSIONS  Our study showed that the free medication period increased the 
quit attempts but the increased in treatment adherence and quit success of the 
participating smokers was not obvious. 
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INTRODUCTION
Smoking is one of the major causes of preventable 
death in the world. In Turkey, its prevalence is 27.1% 
among adults over 15 years of age, with 41.5% for 
males and 13.1% for females1. According to the 
recent Global Adult Tobacco Survey, 46% of Turkish 
smokers tried to quit smoking at least once in the last 
year, of whom 73.4% had tried without assistance2. 
Tobacco use was classified as a disorder associated 
with substance use for the first time in 19942, and 
this disorder needs to be treated accordingly3—
as quit success increases from 7% to 15.7% with 
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assistance4. The most effective method for cessation 
is a combination of cognitive behavioral therapy and 
pharmacotherapy5. There are three types of first choice 
medical treatment in Turkey: nicotine replacement 
therapy (NRT), bupropion, and varenicline6. After 
Turkey signed the World Health Organization 
Framework Convention for Tobacco Control (WHO 
FCTC) in 2004, tobacco control has become of 
fundamental importance in the country. The number 
of smoking cessation clinics has been increasing 
annually; until 2002 there were only 25 SCCs in 
the country while in 2018 there were 4177. SCCs 
provide motivation and appropriate cessation methods 
for smokers and play an important role in cessation 
success. In 2011, for the first time 300000 bupropion 
and varenicline preparations were distributed to SCCs 
by the Turkish Ministry of Health (MoH). They 
repeated this initiative for a second time in 2015 
and continued for 1.5 years. During other periods, 
smokers who wanted to quit smoking would pay for 
prescribed cessation medication themselves8. There 
was one study in Turkey that evaluated the outcomes 
of these two implementations between years 2011 and 
2012 and found lower quit success at 6 months among 
the free-drug user group compared to the group of 
patients who had to pay for their treatment9. There 
is, however, no study that examined the outcome of 
the Turkish MoH second free medication distribution 
period that started in 2015.
Previous studies have proven the effectiveness of 
smoking cessation free-of-charge interventions10-12. 
However, the number of studies that compare the 
effects of free and paid interventions in real-life 
settings are limited, both in Turkey and worldwide9,13. 
In this study we aimed to evaluate the free smoking 
cessation distribution period in 2015 compared with 
other periods, retrospectively. To our knowledge, our 
study is the second to compare these two periods in 
Turkey, giving useful data to show the gaps that must 
be filled to improve tobacco control policies.
METHODS
Setting and samples
The study population was chosen from patients over 
18 years of age who applied to a secondary level 
government hospital’s smoking cessation clinic, 
located in the Eastern Black Sea region of Turkey, 
between 14 July 2014 and 30 June 2017. At that 
time, this SCC was staffed by one pulmonologist 
(certified for SC counselling by the Turkish MoH), 
one nurse, and one medical secretary. It accepted 
patients one day a week for SC counselling. Patients 
were able to make their appointments by calling a 
national appointment’s line via the Turkish MoH. 
At their first visit, patients gave information on their 
medical history, had physical examinations, laboratory 
tests (complete blood cell count and renal and liver 
function tests), chest x-ray, pulmonary function tests 
and an electrocardiography. In their second visit, all 
their information was entered into the Turkish MoH’s 
tobacco addiction treatment monitoring system—
an online system started in April 2015. Before that 
date, patient data were archived in files manually. 
Any doctor who has a certificate to work in SCCs 
can access this online system via a unique username 
and password. The system requires six steps when 
entering patient information. The first step asks for 
sociodemographic data (name, ID number, phone 
number, date of birth, gender, education level, 
occupation). The second step asks questions for 
the Fagerström test for nicotine dependence. The 
third step includes questions about their smoking 
history (date of first cigarette/length of smoking 
habit, number of previous quit attempts, date of last 
quit attempt, and any methods used for previous 
quit attempts). The fourth step evaluates comorbid 
conditions, pregnancy/lactation status for females, and 
disease/medication history. The fifth step evaluates 
symptoms such as: cough, sputum production, 
reduction of exercise capacity, dyspnea, anxiety, chest 
pain, and blood pressure. If possible, exhaled carbon 
monoxide level is included, as well as reason for 
consultation, if needed. The last step gives the total 
Fagerström test score automatically and the planned 
treatment choice is recorded (pharmacotherapy and/
or behavioral). Planned cessation date is recorded and 
an appointment date is given for the second visit. All 
the data are then saved in the system. In their second 
visit, often seven or fourteen days later, quit status 
and adverse reactions are evaluated, and appointments 
planned for other visits. Any new data are recorded 
on the online system.
Patients were manually grouped by their filed 
signed informed consent for proactive counselling and 
treatment choice in monthly groups. Their names, ID 
numbers, phone numbers, and prescribed medications 
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were also recorded manually in a separate notebook. 
At 3 months after their initial visit, they were called 
by phone and asked questions in three areas: number 
of days medication was used, adverse reactions, and 
quit status. 
Inclusion criteria were being older than 18 years 
of age, having been evaluated as a clinically and 
psychiatrically appropriate candidate for smoking 
cessation, the pharmacotherapy started, and 
completing phone calls during the third month. Those 
who did not fall into this category, or could not be 
reached by phone, were excluded.
Grouping of coverage period
Figure 1 shows all three periods of the study: the first 
period was July 2014–April 2015, second period was 
May 2015–December 2016, and the third period was 
January 2017–June 2017. In the second period only, 
smoking cessation medications or SCMs (varenicline 
and bupropion) were distributed to SCCs free-of-
charge.  
Confounding variables
Patients were started on bupropion, varenicline, or 
combined nicotine replacement therapy (cNRT)—




(actively working 8 months)
48 patients,






(actively working 15 months)
346 patients included




(actively working 6 months)
36 patients,






(actively working 29 months)
nicotine patch and nicotine gum. Smokers that used 
the prescribed medication at least 30 days were 
grouped as ‘treatment adherent’; the others who 
used less than 30 days were grouped as ‘treatment 
non-adherent’. Patients who declared that they had 
quit after the planned quit date in their third month 
phone call were classified as ‘quitters’; those who were 
continuing to smoke or relapsed were ‘non-quitters’.
Statistical analysis  
First, descriptive statistics were used for all three 
periods. Admission rates to the SCC were expressed 
as graphs. For univariate and multivariate analysis 
those periods were examined under two groups: free 
medication period (FP) and paid medication period 
(PMP). Afterwards, for the continuous variables a 
t-test was used, while a chi-squared test was used 
for categorial variables. Backward logistic regression 
(LR) was used to determine the effect of confounding 
variables on both periods and also effect of variables 
on treatment adherence and quit success.
Ethical approval was obtained from the local 
ethics committee, and permission for the study 
was also obtained from the General Secretary of 
the hospital.
RESULTS
Admission rates and treatment choices according 
to periods
In total, 733 patients had applied to the SCC during 
the 29-month period (Figure 1). Among them, 
77.7% had applied during the free medication 
distribution period (FP). Furthermore, the mean 
monthly admission number was highest in the free 
period (38 patients, while it was 15 for the first free 
counselling only period and 6 for the last). Different 
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distributions of treatment choices in all periods 
are shown in Figure 2. In the free period, mostly 
bupropion/varenicline were advised, while in the 
first period cNRT was prescribed, and for the last 
period bupropion was the most frequently prescribed 
treatment choice. 
Patient characteristics according to the 
reimbursement periods
For the study, 417 patients met the inclusion criteria 
and therefore statistical analysis was done on their 
data. There were 346 patients in FP and 71 patients in 
PMP (Table 1). Mean age of the study population was 








( 346 )    p
Age, mean±SD 44.0±13.7 42.7±12.5 44.3±13.9 0.343
Gender Male, n (%) 271 (65.0) 50 (70.4) 221 (63.9) 0.35 
Education level, n (%) 
0.72 
Less than 5-years 157 (37.6) 27 (38.0) 130 (37.6)
5-years primary schooling 44 (10.6) 10 (14.0) 34 (9.8)
3-years secondary schooling 136 (32.6) 22 (30.9) 114 (32.9)
3-years high schooling 80 (19.2) 12 (16.9) 68 (19.7)
Occupation, n (%)                              
0.17 
Blue collar worker or farmer 120 (28.7) 22 (31.0) 98 (28.3)
White collar worker 102 (24.4) 18 (25.4) 84 (24.3)
Housewife or not working 100 (23.9) 14 (19.7) 86 (24.9)
Presence of comorbid disease, n (%) 129 (30.9) 29 (40.8) 100 (28.9) 0.047 
Fagerström score, mean±SD 6.47±2.02 5.74±2.16 6.62±1.96 0.002 
≥6, n (%) 293 (70.2) 41 (66.1) 252 (72.8) 0.28 
Started medical treatment, n (%) 
<0.0001
Varenicline      134 (32.1) 10 (14.1) 124 (35.8)
Bupropion 218 (52.2) 38 (53.5) 180 (52.0)
cNRT 65 (15.5) 23 (32.4) 42 (12.1)
Treatment use duration,  mean±SD 20.1±18.3 16.3±17.1 20.8±18.5 0.058 
Treatment adherent (≥30 days), n (%) 162 (38.8) 20 (28.2) 142 (41) 0.043
Control visit number, mean±SD 1.40±1.10 0.74±0.93 1.54±1.09 <0.0001 
Presence of adverse reactions, n (%) 103 (24.7) 15 (21.1) 88 (25.4) 0.44 
Quit smoking, n (%) 149 (35.7) 18 (25.4) 131 (37.9) 0.045 
Table 1. Characteristics of the study population
Bupropion
Paid medication period-1 Paid medication period-2Free period
Bupropion BupropionVarenicline Varenicline VareniclinecNRT cNRT cNRT
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44.0±13.7 years, and in terms of sociodemographic 
characteristics both periods were similar. However, 
the rate of patients with comorbid disease was higher 
in PMP, as was the number of NRT users. The 
rate of bupropion users was similar. Patients who 
sought treatment during the free period had higher 
Fagerström test scores, a higher rate of starting 
varenicline, higher rates of treatment adherence, and 
higher mean control visits. The rate of successful 
quitters was also higher in FP (p<0.05) (Table 1). 
A multivariate analysis with Backward LR test was 
performed among all variables in Table 1; older age, 
higher control visit number, absence of comorbid 
disease, varenicline and bupropion use compared to 
cNRT were associated factors with FP (Table 2). 
Factors affecting treatment adherence
Varenicline and bupropion use were associated with 
increased treatment adherence compared to cNRT; 
varenicline users’ treatment adherence was also 
higher than bupropion users. An absence of adverse 
reactions and a higher number of control visits were 
also associated with higher treatment adherence, both 
in univariate and multivariate analysis. However, the 
FP group’s treatment adherence was significantly 
higher only in univariate analysis (Table 3).
Factors affecting quit success
Older age (middle age and older) were associated 
with higher quit success in both analyses. Varenicline 
use was also associated with higher quit success 
in multivariate analysis. More control visits were 
associated with higher quit success in univariate 
analysis only. Treatment adherence was associated 
with increased quit success as well. Being in the FP 
group was associated with increased quit success only 
in univariate analysis (Table 4). 
Drug distribution differed between periods, 
especially for varenicline and cNRT, and only 
bupropion had similar rates of use in both periods; 
therefore, we evaluated bupropion users’ quit 
success across both periods. Patients in the FP using 
bupropion had higher quit success compared to 
those using it during the NFP (OR=3.554; 95% CI: 
1.322–9.557; p<0.05). Mean bupropion use in the 
FP was also higher compared to PMP; 19.7±15.6 and 
11.2±14.9, respectively (p<0.05).
Table 2. Statistically significantly associated 
characteristics with free period*
Multivariate analysis
(Backward LR)
OR 95% CI p
Age (per 1 age 
increment)
1.032 1.006–1.058 0.014
Control visit number 
(per 1 visit increment)
3.136 2.032–4.838 <0.001




Varenicline 5.948 2.437–14.517 0.023
Bupropion 2.291 1.112–4.680 <0.001
Method: Backward Stepwise (likelihood ratio): –2 Log likehood: 302.889; Cox and 
Snell R2: 0.170; Negelkerke R2: 0.284, Omnibus test of model coefficients: p<0.001.
*Adjusted with all of the variables in Table 1: age, gender, education level, job, 
presence of comorbid diseases, Fagerström score, started medication, treatment 




OR 95% CI p OR 95% CI p
Started treatment choice 
cNRT 1 1
Bupropion                                                                          2.184 1.120–4.261 0.022 3.038 1.460–6.322 0.003
Varenicline 4.645 2.316–9.319 0.001 5.444  2.526–11.684 0.001
Bupropion 1 1
Varenicline 2.127 1.371–3.298 0.001 2.558 1.384–4.725 0.003
Adverse reaction (absence compared to 
presence)
1.765 1.092–2.854 0.020 3.015 1.735–5.238 0.001
Control visit number (per 1 visit increase) 1.718 1.399–2.109 0.001 1.694 1.356–2.117 0.001
Free period compared to not-free period 1.775 1.014–3.107 0.045 – – NS
Table 3. The affector factors on treatment adherence in univariate and multivariate analysis
Method: Backward Stepwise (likelihood ratio): –2 Log likelihood: 475.755; Nagelkerke R2: 0.154; Omnibus test of model coefficients: p=0.000. Analyses were adjusted for age, 
gender, education level, job, comorbid disease, Fagerström test, treatment choice, control visit, adverse reactions, quit status and reimbursement periods.
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DISCUSSION
This study showed that a period of free SC 
medication disbursement increased the number of 
attempts to quit by patients visiting the smoking 
cessation clinic, but the effect on treatment 
adherence and on quit success was not statistically 
significantly different. It also provided evidence that 
the reimbursement status of the medication had an 
effect on the clinician’s treatment choice. The overall 
quit rate at the third month was found to be 35%, 
and the treatment adherence rate was 38%. Treatment 
adherence was found to be the biggest factor in quit 
success. An absence of side effects, increased control 
visits, varenicline use versus bupropion, and being 
in the free medication period group all increased 
treatment adherence. 
It has been suggested that the financial cost of 
SC treatments can act as a barrier to those seeking 
support; the effectiveness of free interventions was 
previously proven in clinical trials14. However, the 
need for studies tracking real-life experiences without 
additional quitting incentives for participants has 
been noted13. Therefore, our study was designed to 
give a real-life experience on the topic. 
The ef f icacy of  f ree-of-charge smoking 
cessation interventions has been proven in studies 
worldwide11,12. Additionally, in a recent study, proof 
of the cost-effectiveness and need for covering the 
cost smoking cessation interventions under insurance 
has been reported10. In another study, full financial 
interventions directed at smokers were found to 
increase the proportion of smokers who attempted 
to quit, used smoking cessation treatments, and 
succeeded in quitting14. However, these studies 
mostly took place in developed countries. There 
was a study that evaluated the nationwide smoking 
cessation intervention periods’ outcomes separately15. 
Also, in another study that was the first to compare 
the outcomes of the free and paid medication periods 
of Turkey between years 2011 and 2012, it was 
found that smokers who used free drugs had lower 
quit rates at 6 months compared to those who paid 
for the medication, 14.8% versus 27.3%9. Our study 
is second in Turkey to directly compare the short-
term outcomes of the free medication period with the 
period in which only counseling is included at no cost. 
However, both the previous study9 and our study have 
some limitations that decrease their power. In both 
studies, different rates of confounder factors such as 
frequency of type of medication, time of usage, mean 
age, mean Fagerström scores of both periods, limit 
the ability to directly evaluate the free period’s effect 
on the outcome. We, however, performed multivariate 
logistic regression analysis with Backward LR test to 
evaluate the factors associated with free period,  which 
was not done in the other study.
In our results, one of the important points is that 




OR 95% CI p OR 95% CI p
Age groups (years)
15–44 1 1
45–64 2.495 1.210–5.418 0.013 1.901 1.080–3.346 0.026
≥65 2.083 0.998–4.347 0.051 3.791 1.574–9.131 0.003
Started treatment choice 
Bupropion 1 1
Varenicline 1.291 0.723–2.305 0.387 1.984 1.071–3.674 0.029
cNRT 0.791 0.430–1.454 0.450 1.613 0.780–3.335 0.197
Control visit number (per 1 visit increase) 1.461 1.210–1.765 0.001 – – NS
Treatment adherent compared to non–
adherent 
3.449 2.266–5.247 0.001 3.056 1.918–4.867 0.001
Free period compared to not–free period 1.794 1.007–3.195 0.047 – – NS
Table 4. The affector factors on quit success in univariate and multivariate analysis
Method: Backward Stepwise (likelihood ratio): –2 Log likelihood: 458.124; Nagelkerke R2: 0.177; Omnibus test of model coefficients: p=0.000. Analyses were adjusted for age, 
gender, education level, job, comorbid disease, Fagerström test, treatment choice, control visit, adverse reactions, treatment adherence, quit status and reimbursement periods.
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that each year most smokers intend to quit, but only 
5% of them succeed because 73.4% of smokers who 
intend to quit try it on their own, without support1. 
Through free medical interventions, smokers who 
want to quit can have a higher chance of success. A 
free period encourages those smokers who are making 
a genuine effort to quit. In an international study, 
during the free reimbursement period telephone 
counselling was 10 times more common than during 
paid periods. Similarly, that study covered two paid 
periods and one free period. In the paid period 
following the year when medication was reimbursed, 
though the percentage of smokers in the population 
did drop by about 3%, the number of patients who 
signed up for SC programs was also at the lowest level 
of the entire study16. In our study, the mean number 
of monthly patient admissions to the SCC was 15 in 
the first PMP; this decreased to 6 in the second PMP 
following the FP. Admissions were highest during the 
free period with 38 patients monthly. The decrease in 
enrollment following the free period may be due to 
smokers anticipating another reimbursement period 
and thus deciding to wait in case it occurs.
Another interesting finding was that only 38% of 
patients were treatment adherent; 41% in FP and 
28.2% in PMP (p<0.05). In multivariate analysis 
the difference between periods was not statistically 
significant. In both periods, medication usage 
durations were still a problem. There is a need to 
evaluate the reasons behind inadequate treatment 
usage and premature discontinuation. In other 
studies, reported explanations included smoking 
relapses, experiencing medication-related side 
effects, and believing that the medication was no 
longer needed17. These could also be issues within 
our study population, however we did not record 
that data specifically in this study. More professional, 
full-time SC interventions and close follow-ups are 
required to educate and give more intensive support 
and information to patients—not only about adverse 
reactions to treatment but about how the mechanism 
works to affect SC. However, in univariate analysis the 
FP was also found to increase the treatment adherence, 
so there is a chance that cost does play a role in early 
treatment cessation. Medication cost was found by 
Iranian researchers18 to have an effect on varenicline 
users. Also, in the same study they found higher quit 
rates in the group that used varenicline over 6 weeks. 
In our study, only the bupropion user groups’ number 
was available for comparisons and multivariate analysis 
according to reimbursement status. Patients in the FP 
using bupropion had both higher quit success and 
treatment usage duration compared to those using it 
during the NFP. Also, treatment adherence of cNRT 
users was lowest because of cost.
In terms of clinician response to the FP, the data 
showed that prescribed treatment choices were 
different in each period. In the first PMP, for example, 
mostly cNRT was prescribed. In the FP, bupropion 
and varenicline had the higher rates of prescription, 
while cNRT had the lowest rate. Finally, in the last 
NFP, bupropion had the highest rate. One of the 
reasons for this result might be the changes in the 
clinician’s experience. At first, due to the potential 
risks of drug-related side effects, mostly cNRTs were 
preferred, because they are thought to cause fewer 
complications. Another explanation may be the cost 
of the medications. Bupropion and varenicline have 
monthly packages, and their monthly costs were 
between 72–110 Turkish lira (TL) for bupropion 
and  195–262 TL for varenicline, during the time 
of the study. For that reason, nicotine patches and 
gums were offered, because that form of treatment 
had weekly packaging, which allowed patients to at 
least try it to see whether it will work. Weekly nicotine 
patch prices were 36–48 TL and nicotine gum prices 
were 20–24 TL; therefore, the monthly cost of cNRT 
was approximately 200 TL, higher than for bupropion. 
In the last PMP, bupropion was mostly offered—that 
is strongly related to the cost of the drugs, because 
the monthly cost of bupropion was lowest. Physicians 
also observed that offering cNRT caused premature 
discontinuation; because of the cost, patients only 
bought one pack of patches and gum (adequate for 
only 1 week). Therefore, in the last period bupropion 
was chosen. In the FP, mostly free medications of 
varenicline and bupropion were started, for obvious 
reasons. Thus, our results also show that the cost 
of the medication is a potential barrier in cessation 
interventions. Excluding this barrier will positively 
affect SC interventions, as discussed previously19.
Benli et al.20 conducted a study in 2011, during the 
first free medication period, and found the quit rate to 
be 25.9% at the third month. Longer medication usage 
was associated with higher quit rates. In the same 
study, the quit rate at the 6th month was found to be 
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down to 15.8%, and they suggested that one of the 
reasons for the low success was the free medication 
distribution itself. Smokers without the intent and 
willingness to quit had just rushed to get medication 
when it was available. This theory is backed up by 
other research—in evaluations after one of the free 
distribution periods (which can last up to 1.5 years), 
it was found that some of the patients had not even 
started to use the medication prescribed. In another 
recent national study, Önur et al.21 found the quit rate 
during a paid medication period to be 25% at the 6th 
month; and that each member of the quitter group 
had followed up with control visits at least once. It 
is worth mentioning that the mean participant ages 
were different between these studies: 35 years for the 
Benli et al. study and 45 years for the Önür et al. This 
variable may be one of the factors for the difference in 
quit rates; as previous research has shown that older 
patients are more likely to have symptoms from long-
term smoking and are thus more motivated to quit22. 
In our study as well, older age groups had higher 
quit rates in multivariate analysis, as did varenicline 
users and those who continued their medication for at 
least 30 days. The difference in quit rates between the 
various medications is likely due to the metabolism 
and mechanism of the drugs, as reported previously23. 
In univariate analysis, higher numbers of control visits 
and being in the FP, as opposed to the PMP, also 
resulted in statistically significant higher quit rates. 
Limitations
This study is the second to compare the free and paid 
periods of medication disbursement within the recent 
Turkish tobacco control policy. It is a study of real-life 
experiences from the same clinic and pulmonologist, 
but as it was performed at a specific location it may not 
be generalizable globally. Furthermore, evaluations 
of quit status depended on self-reports and is one 
of the limitations, however, previous studies have 
shown that discrepancies between self-reported and 
biochemically verified smoking status are minimal 
among the general population, even in special patients 
groups24-26. Also, heterogeneous distribution of patient 
characteristics such as age, comorbid condition status 
and started treatment choice may have an influence 
on the results. Additionally, due to the retrospective 
design of the study all of the patients could not be 
included because of incomplete data.
CONCLUSIONS
The current study makes it apparent that free SC 
medication distribution, in the Eastern Black Sea 
region of Turkey, increased quit attempts but the 
increase in treatment adherence and quit success of 
the participating smokers was not obvious. One of the 
reasons for this result could be the heterogeneous 
characteristic distribution of patients between the 
groups. Only the patients who started bupropion 
were available for multivariate analysis, therefore 
only those patients were evaluated according to their 
reimbursement status and among them significantly 
higher treatment adherence and quit success rates 
were detected in FP, compared to patients who used 
bupropion in PMP. More studies with homogeneous 
patient distribution for minimizing confounding 
factors are required to compare the outcomes of both 
periods. Interestingly, it was also discovered that the 
cost of the medications directly affected the clinicians’ 
treatment choices because SCMs can be costly for 
some smokers. There is a need at all times to cover 
SCMs under insurance, like other treatment choices, 
so that smokers can apply when they feel ready to quit. 
Additionally, SCC teams should prioritize closer follow-
ups and spend more time on pretreatment education 
and motivation. In this way clinicians can maximize 
the positive effects of the free period and increase quit 
success rates consistently. 
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